The biopharmaceutical company announced earlier this week that it had completed recruiting the patients needed for its phase III study. This aims to assess the effectiveness of a drug used in the treatment of high blood pressure.
Full team for Quantum Genomics, which can complete its phase III study | Photo credits: Quantum Genomics
Quantum Genomics started the week with a smile, having completed the recruitment of patients planned for its phase III study. This, called FRESH, will allow the company to assess ” the efficacy of firibastat in the treatment of difficult to treat and resistant hypertension “.
The biopharmaceutical company, specializing in the development of a new class of cardiovascular drugs, sought its patients through nearly 70 hospitals in Europe, Canada, the United States and Latin America. All of his patients suffer from so-called arterial hypertension. difficult to treat or resistant and followed a very strict study protocol.
First results at the end of October
” According to the study protocol, the patients received for three months, in addition to their current treatment comprising at least two classes of antihypertensive drugs, either firibastat (…) or a placebo treatment “, comments the company in its press release. At the end of these three months, the reduction in blood pressure is evaluated as a priority, after which Quantum Genomis looked at a few secondary criteria, ” ambulatory blood pressure measurements, the percentage of patients at target blood pressure, as well as blood concentrations of several biomarkers (…) No serious treatment-related adverse events were reported. »
With the visit of the last patient included, which takes place, as planned, after three months of treatment and one month of follow-up, the company is aiming for the first results at the end of October 2022. compatible with a presentation at the American Heart Association Convention in Chicago November 5-7, 2022 “.
THE